Curative Radiation Therapy for Pancreatic Malignancies

Surgical Clinics of North America

Volumn 90, Issue 2, 2010, Pages 341-354

  Cooke, Ellen W ^a   Hazard, Lisa ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Gemcitabine; Pancreatic cancer; Radiotherapy

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; MITOMYCIN; STREPTOZOCIN; TNFERADE; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; BLOOD TOXICITY; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTRAOPERATIVE RADIOTHERAPY; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PANCREAS SURGERY; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIATION FIELD; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, RADIATION; FLUOROURACIL; HUMANS; PANCREATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 77950797363     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2009.12.002     Document Type: Review

References (42)

1. American Cancer Society Cancer facts and figures 2009 2009, American Cancer Society, Atlanta (GA).
2. SEER database Cancer statistics, section: pancreas, Table 22.7 Available at:, Accessed September 9, 2009. http://seer.cancer.gov/csr/1975_2006/browse_csr.php?section=22&page=sect_22_table.07.html.
3. Knaebel H.P., Marten A., Schmidt J., et al. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma-CapRI: study protocol [ISRCTN62866759]. BMC Cancer 2005, 5:37.
4. Oettle H., Post S., Neuhaus P., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297:267.
5. Kalser M.H., Ellenberg S.S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120:899.
6. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 1987, 59:2006.
7. Klinkenbijl J.H., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999, 230:776.
8. Neoptolemos J.P., Dunn J.A., Stocken D.D., et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001, 358:1576.
9. Regine W.F., Winter K.A., Abrams R.A., et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008, 299:1019.
10. John M., Pajak T., Flam M., et al. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08. Cancer J Sci Am 1996, 2:205.
11. Overgaard J., Hjelm-Hansen M., Johansen L.V., et al. Comparison of conventional and split-course radiotherapy as primary treatment in carcinoma of the larynx. Acta Oncol 1988, 27:147.
12. Withers H.R., Taylor J.M., Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988, 27:131.
13. Withers H.R., Peters L.J., Taylor J.M. Dose-response relationship for radiation therapy of subclinical disease. Int J Radiat Oncol Biol Phys 1995, 31:353.
14. Garton G.R., Gunderson L.L., Nagorney D.M., et al. High-dose preoperative external beam and intraoperative irradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 1993, 27:1153.
15. Mohiuddin M., Cantor R.J., Biermann W., et al. Combined modality treatment of localized unresectable adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1988, 14:79.
16. Mohiuddin M., Regine W.F., Stevens J., et al. Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas. J Clin Oncol 1995, 13:2764.
17. Roldan G.E., Gunderson L.L., Nagorney D.M., et al. External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer 1988, 61:1110.
18. Moertel C.G., Frytak S., Hahn R.G., et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 1981, 48:1705.
19. Small W., Berlin J., Freedman G.M., et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2008, 26:942.
20. Moody J.S., Sawrie S.M., Kozak K.R., et al. Adjuvant radiotherapy for pancreatic cancer is associated with a survival benefit primarily in stage IIB patients. J Gastroenterol 2009, 44:84.
21. Desai S., Ben-Josef E., Griffith K.A., et al. Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer. Int J Radiat Oncol Biol Phys 2009, 75:1450-1455.
22. Marten A., Schmidt J., Ose J., et al. A randomized multicentre phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival-CapRI-2. BMC Cancer 2009, 9:160.
23. Crane C.H., Ellis L.M., Abbruzzese J.L., et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 2006, 24:1145.
24. Crane C.H., Winter K., Regine W.F., et al. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol 2009, 27:4096.
25. Duffy A., Kortmansky J., Schwartz G.K., et al. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol 2008, 19:86.
26. Iannitti D., Dipetrillo T., Akerman P., et al. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol 2005, 28:570.
27. Willett C.G., Del Castillo C.F., Shih H.A., et al. Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer. Ann Surg 2005, 241:295.
28. Loehrer P., Cardenes H., wagner L., et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201 [abstract 4506]. J Clin Oncol 2008, 26(Suppl).
29. Burris H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403.
30. Huguet F., Andre T., Hammel P., et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007, 25:326.
31. Brown M.W., Ning H., Arora B., et al. A dosimetric analysis of dose escalation using two intensity-modulated radiation therapy techniques in locally advanced pancreatic carcinoma. Int J Radiat Oncol Biol Phys 2006, 65:274.
32. Milano M.T., Chmura S.J., Garofalo M.C., et al. Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2004, 59:445.
33. Ben-David M.A., Griffith K.A., Abu-Isa E., et al. External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2006, 66:772.
34. Crane C.H., Antolak J.A., Rosen I.I., et al. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer 2001, 30:123.
35. Hoyer M., Roed H., Traberg Hansen A., et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 2006, 45:823.
36. Chang D.T., Schellenberg D., Shen J., et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 2009, 115:665.
37. Koong A.C., Le Q.T., Ho A., et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004, 58:1017.
38. Koong A.C., Christofferson E., Le Q.T., et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005, 63:320.
39. Sindelar W.F., Kinsella T.J. Studies of intraoperative radiotherapy in carcinoma of the pancreas. Ann Oncol 1999, 10(Suppl 4):226.
40. Tepper J.E., Noyes D., Krall J.M., et al. Intraoperative radiation therapy of pancreatic carcinoma: a report of RTOG-8505. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1991, 21:1145.
41. Crane C.H., Abbruzzese J.L., Evans D.B., et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?. Int J Radiat Oncol Biol Phys 2002, 52:1293.
42. McGinn C.J., Zalupski M.M., Shureiqi I., et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001, 19:4202.